Connect with us

Published

on

Many Americans really want to lose weight and a new poll shows nearly half of adults would be interested in taking a prescription drug to help them do so. Use Our Content

It can be republished for free.

At the same time, enthusiasm dims sharply if the treatment comes as an injection, if it is not covered by insurance, or if the weight is likely to return after discontinuing treatment, a new nationwide KFF poll found.

Those findings display the enthusiasm for a new generation of pricey weight loss drugs hitting the market and illustrate possible stumbling blocks, as users potentially must deal with weekly self-injections, lack of insurance coverage, and the need to continue the medications indefinitely.

For example, interest dropped to 14% when respondents were asked if they would still consider taking prescription medications if they knew they could regain weight after stopping the drugs.

One way to interpret that finding is people want to lose a few pounds but dont want to be on a drug for the rest of their life, said Ashley Kirzinger, KFFs director of survey methodology. The monthly poll reached out to 1,327 U.S. adults.

The U.S. represents a large market for drugmakers who want to sell weight loss prescriptions: An estimated 42% of the population is classified as obese, according to a controversial metric known as BMI, or body mass index. In the KFF poll, 61% said they were currently trying to lose weight, although only 4% were taking a prescription medication to do so.

That gap between the 4% taking any kind of prescription weight loss treatment and the number of Americans deemed overweight or obese is the sweet spot drugmakers are targeting for the new drugs, which include several diabetes treatments repurposed as weight loss drugs.

The drugs have attracted much attention, both in mainstream publications and broadcasts and on social media, where they are often touted by celebrities and other influencers. Demand jumped and supplies have become limited. About 7 in 10 adults had heard at least a little about the new drugs, according to the survey.

The newer treatments include Wegovy, a slightly higher dose of Novo Nordisks diabetes drug Ozempic, and Mounjaro, an Eli Lilly diabetes treatment for which the company is currently seeking FDA approval as a weight loss drug.

Weight loss with these injectable drugs surpasses those of earlier generations of weight loss medications. But they are also costlier than previous drugs. The monthly costs of the drugs set by the drugmakers can range from $900 to more than $1,300.

At, say, a wholesale price tag of $1,350, the tab per person could top $323,000 over 20 years. Email Sign-Up

Subscribe to KFF Health News' free Morning Briefing. Your Email Address Sign Up

The drugs appear to work by mimicking a hormone that helps decrease appetite.

Still, like all drugs, they come with side effects, which can include nausea, diarrhea, vomiting, and constipation. More serious side effects include the risk of a type of thyroid cancer, inflammation of the pancreas, or low blood sugar. Health officials in Europe are investigating reports that the drugs may result in other side effects like suicidal thoughts.

The KFF survey found that 80% of adults thought insurers should cover the new weight loss drugs for those diagnosed as overweight or obese. Just over half wanted it covered for anyone who wanted to take it. Half would still support insurance coverage even if doing so could increase everyones monthly premiums. Still, 16% of those surveyed said they would be interested in a weight loss prescription even if their insurance did not cover it.

In practice, coverage for the new treatments varies, and private insurers often peg coverage to patients BMI, a ratio of height to weight. Medicare specifically bars coverage for drugs for anorexia, weight loss, or weight gain, although it pays for bariatric surgery.

Unfortunately, a lot of insurers have not caught up to the idea of recognizing obesity as a disease, said Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School.

Employers and insurers must consider the potential costs of covering the drugs for enrollees perhaps for them to use indefinitely against the potential savings associated with losing weight, such as a lower chance of diabetes or joint problems.

Stanford said the drugs are not a miracle cure and do not work for everyone. But for those who benefit, it can be significantly life-altering in a positive way, she said.

Its not surprising, she added, that the drugs may need to be taken long term, as the idea that there is a quick fix doesnt reflect the complexity of obesity as a disease.

While the drugs currently on the market are injectables, some drugmakers are developing oral weight loss drugs, although it is unclear whether the prices will be the same or less than the injectable products.

Still, many experts predict that a lot of money will be spent on weight loss products in the coming years. In a recent report, Morgan Stanley analysts called obesity the new hypertension and predicted industry revenue from U.S. sales of obesity drugs could rise from a current $1.6 billion annually to $31.5 billion by 2030.

Julie Appleby: jappleby@kff.org, @Julie_appleby Related Topics Health Industry Pharmaceuticals Drug Costs KFF Obesity Prescription Drugs Contact Us Submit a Story Tip

Continue Reading

Sports

Danault’s last-minute goal saves Kings in wild G1

Published

on

By

Danault's last-minute goal saves Kings in wild G1

LOS ANGELES — Phillip Danault scored his second goal with 42 seconds to play, and the Los Angeles Kings blew a four-goal lead before rallying for a 6-5 victory over the Edmonton Oilers in the opener of the clubs’ fourth consecutive first-round playoff series Monday night.

The Kings led 5-3 in the final minutes before Zach Hyman and Connor McDavid tied it with an extra attacker. Los Angeles improbably responded, with Danault skating up the middle and chunking a fluttering shot home while a leaping Warren Foegele screened goalie Stuart Skinner.

Andrei Kuzmenko had a goal and two assists in his Stanley Cup playoff debut, and Adrian Kempe added another goal and two assists for the second-seeded Kings, who lost those last three series against Edmonton. Los Angeles became the fourth team in Stanley Cup playoffs history to win in regulation despite blowing a four-goal lead.

Quinton Byfield, Phillip Danault and Kevin Fiala also scored, and Darcy Kuemper made 20 saves in his first playoff start since raising the Cup with Colorado in 2022.

Los Angeles has home-ice advantage this spring for the first time in its tetralogy with Edmonton, and the Kings surged to a 4-0 lead late in the second period in the arena where they had the NHL’s best home record. That’s when the Oilers woke up and made it a memorable night: Leon Draisaitl, Mattias Janmark and Corey Perry scored before Hyman scored with 2:04 left and McDavid scored an exceptional tying goal with 1:28 remaining.

McDavid had a goal and three assists for the Oilers, who reached Game 7 of the Stanley Cup Final last season. Skinner stopped 24 shots.

Game 2 is Wednesday night in Los Angeles.

Until Edmonton’s late rally, Kuzmenko was the star. Los Angeles went 0 for 12 on the power play against Edmonton last spring, but the 29-year-old Russian — who has energized the Kings since arriving last month — scored during a man advantage just 2:49 in.

Continue Reading

Sports

Skinner finally makes playoff debut, gets assist

Published

on

By

Skinner finally makes playoff debut, gets assist

LOS ANGELES — Edmonton Oilers forward Jeff Skinner finally made his Stanley Cup playoff debut after 15 seasons and a league-record 1,078 regular-season games.

Skinner was in the lineup for Edmonton’s 6-5 loss in Game 1 of its first-round series against the Los Angeles Kings on Monday night, ending the longest wait for a postseason debut in NHL history.

Skinner, who turns 33 years old next month, has been an NHL regular since he was 18. He has racked up six 30-goal seasons and 699 total points while scoring 373 goals in a standout career.

But Skinner spent his first eight seasons of that career with the Carolina Hurricanes, at the time, a developing club that missed nine consecutive postseasons during the 2010s. From there, he spent the next six seasons with the woebegone Buffalo Sabres, whose current 14-season playoff drought is the league’s longest.

Skinner signed with Edmonton as a free agent last summer but struggled to nail down a consistent role in the Oilers’ lineup in the first half of the season. His game improved markedly in the second half, and he scored 16 goals this season while entering the playoffs as Edmonton’s third-line left wing.

Skinner’s teammates have been thrilled to end his drought this month. Connor McDavid presented Skinner with their player of the game award after the Oilers clinched their sixth straight playoff berth two weeks ago.

The veteran was active against the Kings, as his club mounted a furious rally only to lose in the final minute of regulation. Skinner had an assist and five hits across his 15 shifts. He finished the night with 11:12 time on the ice.

The Associated Press contributed to this report.

Continue Reading

US

Harvard University sues over $2.2bn funding freeze after rejecting demands from Donald Trump’s administration

Published

on

By

Harvard University sues over .2bn funding freeze after rejecting demands from Donald Trump's administration

Harvard University is suing Donald Trump’s administration after it rejected a list of demands from the White House and had $2.2bn (£1.6bn) of government funding frozen.

The Ivy League institution, in Cambridge, Massachusetts, is accused of ideological bias and allowing antisemitism during campus protests last year against Israel’s war in Gaza.

The Trump administration, which began a review of $9bn (£6.7bn) in federal grants for Harvard in March, had demanded the university screen international students for those “hostile to the American values” and the end of all diversity, equality and inclusion programmes.

FILE PHOTO: Demonstrators rally on Cambridge Common in a protest organized by the City of Cambridge calling on Harvard leadership to resist interference at the university by the federal government in Cambridge, Massachusetts, U.S. April 12, 2025. REUTERS/Nicholas Pfosi/File Photo
Image:
Protesters earlier this month at Harvard called on the university to resist interference by the federal government. Pic: Reuters

Students, faculty and members of the Harvard University community rally against Donald Trump's funding  policies, Thursday, April 17, 2025, in Cambridge, Mass. (AP Photo)
Image:
Students at a rally last week at Harvard against Donald Trump’s funding policies. Pic: AP

The university’s president Alan Garber has remained defiant and rejected those and other reforms, prompting the US President to question whether the university should lose its tax-exempt status.

Mr Trump accused the institution of pushing what he called “political, ideological, and terrorist inspired/supporting ‘Sickness?'” in a post on Truth Social.

Harvard has seen student-led protests in recent days calling on the institution to resist interference by the federal government.

Harvard’s lawsuit, filed in Boston, described the research funding freeze as “arbitrary and capricious” and violating its First Amendment rights.

More on Donald Trump

“The government has not – and cannot – identify any rational connection between antisemitism concerns and the medical, scientific, technological, and other research it has frozen that aims to save American lives, foster American success, preserve American security, and maintain America’s position as a global leader in innovation,” the court documents revealed.

A person relaxes on the Harvard University campus on Thursday, as the US Supreme Court announced its historic ruling Pic: AP
Image:
Harvard University has rejected a series of demands from the White House. File pic: AP

On Monday, White House spokesperson Harrison Fields issued a defiant response to the lawsuit: “The gravy train of federal assistance to institutions like Harvard, which enrich their grossly overpaid bureaucrats with tax dollars from struggling American families is coming to an end.

“Taxpayer funds are a privilege, and Harvard fails to meet the basic conditions required to access that privilege.”

The Trump administration has also paused some funding for universities including Columbia, Princeton, Cornell, Northwestern and Brown over the campus protests.

Read more from Sky News:
Turkish student detained at university
Is Trump’s deportation policy firm or cruel?
Anti-Trump protests sweep America

But protesters, including some Jewish groups, say their criticism of Israel’s military actions in Gaza is wrongly associated with antisemitism.

Mr Garber said the institution would continue to fight hate and fully comply with anti-discrimination laws.

A drone view shows an encampment at Harvard University where students protest in support of Palestinians in Cambridge, Massachusetts.
Pic: Reuters
Image:
A small encampment in support of Palestinians at the Harvard campus in April 2024. Pic: Reuters

The American Council on Education, a non-profit organisation with more than 1,600 member colleges and universities, supported the legal action by Harvard.

“It has been clear for weeks that the administration’s actions violated due process and the rule of law. We applaud Harvard for taking this step.”

Continue Reading

Trending